Exploring use of monoclonal antibodies for advanced cholesterol control in moderate risk patients.

Injectable monoclonal antibody medications [PCSK9] are the first new drugs in decades to dramatically improve the outlook for patients with coronary artery disease. However, they have only been approved for the highest risk patients, those who have had events such as heart attack or stroke. In this research, Evolocumab [Repatha] will be studied in patients who have neither had heart attacks nor strokes to determine if similar powerful findings are present. Eligible subjects will be randomized 1:1 to either receive Evolocumab [Repatha] or standard therapy. Patients will be followed for four years.

(R. Karlsberg, MD; B. Samuels, MD)